Estimates of protection levels against SARS-CoV-2 infection and severe COVID-19 in Germany before the 2022/2023 winter season: the IMMUNEBRIDGE project.

Autor: Lange B; Department of Epidemiology, Helmholtz Centre for Infection Research (HZI), Brunswick, Germany. Berit.Lange@helmholtz-hzi.de.; German Center for Infection Research (DZIF), TI BBD, Brunswick, Germany. Berit.Lange@helmholtz-hzi.de., Jaeger VK; Institute of Epidemiology and Social Medicine, University of Münster, Münster, Germany., Harries M; Department of Epidemiology, Helmholtz Centre for Infection Research (HZI), Brunswick, Germany., Rücker V; Institute of Clinical Epidemiology and Biometry, Julius-Maximilians-Universität Würzburg, Würzburg, Germany., Streeck H; Institute of Virology, Medical Faculty, University of Bonn, Bonn, Germany.; German Center for Infection Research (DZIF), Partner Site Bonn-Cologne, Brunswick, Germany., Blaschke S; Emergency Department, University Medical Center Göttingen, Göttingen, Germany., Petersmann A; Institute of Clinical Chemistry and Laboratory Medicine, University Medicine Oldenburg, Oldenburg, Germany.; Institute of Clinical Chemistry and Laboratory Medicine, University Medicine Greifswald, Greifswald, Germany., Toepfner N; Department of Pediatrics, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany., Nauck M; Institute of Clinical Chemistry and Laboratory Medicine, University Medicine Greifswald, Greifswald, Germany.; DZHK (German Centre for Cardiovascular Research), Partner Site Greifswald, University Medicine Greifswald, Greifswald, Germany., Hassenstein MJ; Department of Epidemiology, Helmholtz Centre for Infection Research (HZI), Brunswick, Germany., Dreier M; Institute for Epidemiology, Social Medicine and Health Systems Research, Hannover Medical School, Hannover, Germany., von Holt I; Institute for Epidemiology, Social Medicine and Health Systems Research, Hannover Medical School, Hannover, Germany., Budde A; Institute of Virology, Medical Faculty, University of Bonn, Bonn, Germany.; German Center for Infection Research (DZIF), Partner Site Bonn-Cologne, Brunswick, Germany., Bartz A; Institute of Epidemiology and Social Medicine, University of Münster, Münster, Germany., Ortmann J; Department of Epidemiology, Helmholtz Centre for Infection Research (HZI), Brunswick, Germany., Kurosinski MA; Institute of Epidemiology and Social Medicine, University of Münster, Münster, Germany., Berner R; Department of Pediatrics, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany., Borsche M; Institute of Neurogenetics, University of Lübeck, Lübeck, Germany., Brandhorst G; Institute of Clinical Chemistry and Laboratory Medicine, University Medicine Oldenburg, Oldenburg, Germany., Brinkmann M; Institute for Epidemiology, Social Medicine and Health Systems Research, Hannover Medical School, Hannover, Germany., Budde K; Institute of Clinical Chemistry and Laboratory Medicine, University Medicine Greifswald, Greifswald, Germany., Deckena M; MVZ Labor Krone GbR, Bad Salzuflen, Germany., Engels G; Department of Pediatrics, University Hospital Würzburg, Würzburg, Germany., Fenzlaff M; Institute of Clinical Chemistry and Laboratory Medicine, University Medicine Greifswald, Greifswald, Germany., Härtel C; Department of Pediatrics, University Hospital Würzburg, Würzburg, Germany., Hovardovska O; Department of Epidemiology, Helmholtz Centre for Infection Research (HZI), Brunswick, Germany., Katalinic A; Institute of Social Medicine and Epidemiology, University of Luebeck, Luebeck, Germany., Kehl K; Institute of Virology, Medical Faculty, University of Bonn, Bonn, Germany.; German Center for Infection Research (DZIF), Partner Site Bonn-Cologne, Brunswick, Germany., Kohls M; Institute of Clinical Epidemiology and Biometry, Julius-Maximilians-Universität Würzburg, Würzburg, Germany., Krüger S; Dimap, das Institut Für Markt- Und Politikforschung GmbH, Bonn, Germany., Lieb W; Institute of Epidemiology, Christian-Albrechts-University of Kiel, Kiel, Germany., Meyer-Schlinkmann KM; MVZ Labor Krone GbR, Bad Salzuflen, Germany., Pischon T; Molecular Epidemiology Research Group, Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany.; Biobank Technology Platform, Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany.; Charité-Universitätsmedizin Berlin, Berlin corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany., Rosenkranz D; Institute of Clinical Chemistry and Laboratory Medicine, University Medicine Oldenburg, Oldenburg, Germany., Rübsamen N; Institute of Epidemiology and Social Medicine, University of Münster, Münster, Germany., Rupp J; Department of Infectious Diseases and Microbiology, University Hospital Schleswig-Holstein, German Center for Infection Research (DZIF), Partner Site Hamburg-Lübeck-Borstel-Riems, Lübeck, Germany., Schäfer C; Institute of Clinical Chemistry and Laboratory Medicine, University Medicine Greifswald, Greifswald, Germany., Schattschneider M; Institute of Clinical Chemistry and Laboratory Medicine, University Medicine Greifswald, Greifswald, Germany., Schlegtendal A; University Children's Hospital, Ruhr University Bochum, Bochum, Germany., Schlinkert S; Dimap, das Institut Für Markt- Und Politikforschung GmbH, Bonn, Germany., Schmidbauer L; Institute of Clinical Epidemiology and Biometry, Julius-Maximilians-Universität Würzburg, Würzburg, Germany., Schulze-Wundling K; Institute of Virology, Medical Faculty, University of Bonn, Bonn, Germany.; German Center for Infection Research (DZIF), Partner Site Bonn-Cologne, Brunswick, Germany., Störk S; Department of Clinical Research and Epidemiology, Comprehensive Heart Failure Center (CHFC), and Department of Internal Medicine I, University Hospital Würzburg, Würzburg, Germany., Tiemann C; MVZ Labor Krone GbR, Bad Salzuflen, Germany., Völzke H; Institute for Community Medicine, University Medicine Greifswald, Greifswald, Germany., Winter T; Institute of Clinical Chemistry and Laboratory Medicine, University Medicine Greifswald, Greifswald, Germany., Klein C; Institute of Neurogenetics, University of Lübeck, Lübeck, Germany., Liese J; Department of Pediatrics, University Hospital Würzburg, Würzburg, Germany., Brinkmann F; University Children's Hospital, Ruhr University Bochum, Bochum, Germany., Ottensmeyer PF; Institute of Virology, Medical Faculty, University of Bonn, Bonn, Germany.; German Center for Infection Research (DZIF), Partner Site Bonn-Cologne, Brunswick, Germany., Reese JP; Institute of Clinical Epidemiology and Biometry, Julius-Maximilians-Universität Würzburg, Würzburg, Germany.; Institute for Medical Data Science, University Hospital Würzburg, Würzburg, Germany., Heuschmann P; Institute of Clinical Epidemiology and Biometry, Julius-Maximilians-Universität Würzburg, Würzburg, Germany.; Institute for Medical Data Science, University Hospital Würzburg, Würzburg, Germany.; Clinical Trial Center, University Hospital Würzburg, Würzburg, Germany., Karch A; Institute of Epidemiology and Social Medicine, University of Münster, Münster, Germany. akarch@uni-muenster.de.
Jazyk: angličtina
Zdroj: Infection [Infection] 2024 Feb; Vol. 52 (1), pp. 139-153. Date of Electronic Publication: 2023 Aug 02.
DOI: 10.1007/s15010-023-02071-2
Abstrakt: Purpose: Despite the need to generate valid and reliable estimates of protection levels against SARS-CoV-2 infection and severe course of COVID-19 for the German population in summer 2022, there was a lack of systematically collected population-based data allowing for the assessment of the protection level in real time.
Methods: In the IMMUNEBRIDGE project, we harmonised data and biosamples for nine population-/hospital-based studies (total number of participants n = 33,637) to provide estimates for protection levels against SARS-CoV-2 infection and severe COVID-19 between June and November 2022. Based on evidence synthesis, we formed a combined endpoint of protection levels based on the number of self-reported infections/vaccinations in combination with nucleocapsid/spike antibody responses ("confirmed exposures"). Four confirmed exposures represented the highest protection level, and no exposure represented the lowest.
Results: Most participants were seropositive against the spike antigen; 37% of the participants ≥ 79 years had less than four confirmed exposures (highest level of protection) and 5% less than three. In the subgroup of participants with comorbidities, 46-56% had less than four confirmed exposures. We found major heterogeneity across federal states, with 4-28% of participants having less than three confirmed exposures.
Conclusion: Using serological analyses, literature synthesis and infection dynamics during the survey period, we observed moderate to high levels of protection against severe COVID-19, whereas the protection against SARS-CoV-2 infection was low across all age groups. We found relevant protection gaps in the oldest age group and amongst individuals with comorbidities, indicating a need for additional protective measures in these groups.
(© 2023. The Author(s).)
Databáze: MEDLINE
Externí odkaz: